Almirall, S.A./€ALM
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Almirall, S.A.
Almirall, S.A. is a pharmaceutical company headquartered in Barcelona, Spain. It specializes in the development and commercialization of proprietary medicines, with a focus on dermatology and other specialist-driven therapeutic areas. Almirall's notable products target conditions such as psoriasis, atopic dermatitis, and actinic keratosis. Founded in 1943, the company has expanded its geographical footprint across Europe and North America through strategic acquisitions and partnerships. Almirall emphasizes research and development, maintaining a pipeline of innovative treatments aimed at unmet medical needs. Its strategic positioning is reinforced by collaborations with healthcare professionals and institutions to enhance patient care.
Ticker
€ALM
Sector
Primary listing
BME
Employees
2,084
Headquarters
Website
Almirall, S.A. Metrics
BasicAdvanced
€2.4B
110.98
€0.10
0.34
€0.15
1.34%
Price and volume
Market cap
€2.4B
Beta
0.34
52-week high
€11.32
52-week low
€9.81
Average daily volume
17K
Dividend rate
€0.15
Financial strength
Current ratio
2.392
Quick ratio
1.732
Long term debt to equity
25.007
Total debt to equity
26.466
Dividend payout ratio (TTM)
122.78%
Interest coverage (TTM)
3.69%
Profitability
EBITDA (TTM)
178.601
Gross margin (TTM)
76.05%
Net profit margin (TTM)
2.02%
Operating margin (TTM)
5.47%
Effective tax rate (TTM)
47.13%
Revenue per employee (TTM)
€510,000
Management effectiveness
Return on assets (TTM)
1.56%
Return on equity (TTM)
1.45%
Valuation
Price to earnings (TTM)
110.983
Price to revenue (TTM)
2.237
Price to book
1.64
Price to tangible book (TTM)
5.17
Price to free cash flow (TTM)
99.512
Free cash flow yield (TTM)
1.00%
Free cash flow per share (TTM)
0.112
Dividend yield (TTM)
1.34%
Growth
Revenue change (TTM)
13.13%
Earnings per share change (TTM)
-160.00%
3-year revenue growth (CAGR)
7.18%
10-year revenue growth (CAGR)
2.77%
3-year earnings per share growth (CAGR)
-13.89%
10-year earnings per share growth (CAGR)
-28.36%
10-year dividend per share growth (CAGR)
-0.51%
Bulls say / Bears say
Almirall started 2025 strong: Q1 net sales rose 15% to €285 million, EBITDA climbed 35% to €71 million, and net income jumped 192% to €21.6 million—all outperforming expectations and improving the balance sheet by reducing net debt (Investing.com).
The company’s biologics remain on track: Ilumetri® sales were up 12.7% to €55.1 million, while Ebglyss® sales more than quadrupled to €19 million in Q1. Ebglyss is now available in 13 European markets with plans for further expansion this year (Investing.com).
Almirall reaffirmed its full-year 2025 targets for 10–13% net sales growth and €220–240 million EBITDA, showing management’s confidence in its sustainable growth outlook (Investing.com).
Almirall’s revenues are heavily concentrated in Europe, with over 91% of net sales coming from this region while the US and RoW each contribute less than 5%, leaving the company vulnerable to region-specific regulatory and reimbursement challenges (Investing.com).
Key pipeline assets—including the anti-IL-1RAP monoclonal antibody (ALM27134) and the IL-2muFc candidate—are still in Phase I, with no late-stage candidates likely before 2026. This heightens clinical and regulatory execution risks (BusinessWire).
Despite growth for Ilumetri®, its market share and pricing could face downward pressure as competition in the IL-23 class increases. The company itself noted “growing competition” in the psoriasis market, even though the drug posted strong Q1 sales (BioSpace).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Almirall, S.A. stock?
Almirall, S.A. (ALM) has a market cap of €2.4B as of September 14, 2025.
What is the P/E ratio for Almirall, S.A. stock?
The price to earnings (P/E) ratio for Almirall, S.A. (ALM) stock is 110.98 as of September 14, 2025.
Does Almirall, S.A. stock pay dividends?
Yes, the Almirall, S.A. (ALM) stock pays dividends to shareholders. As of September 14, 2025, the dividend rate is €0.14904 and the yield is 1.34%. Almirall, S.A. has a payout ratio of 122.78% on a trailing twelve-month basis.
When is the next Almirall, S.A. dividend payment date?
The next Almirall, S.A. (ALM) dividend payment date is unconfirmed.
What is the beta indicator for Almirall, S.A.?
Almirall, S.A. (ALM) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.